The anti-vascular endothelial growth factor-A (VEGFA) monoclonal antibody bevacizumab (Avastin®) is used extensively to treat recurrent disease in patients with ovarian cancer and patients with glioblastoma who have failed first line therapy (1–3). Here, VEGFA is linked to ovarian cancer.